{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T09:55:21Z","timestamp":1769939721046,"version":"3.49.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01514","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T04:42:48Z","timestamp":1580445768000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Modeling HIV Pre-Exposure Prophylaxis"],"prefix":"10.3389","volume":"10","author":[{"given":"Thomas","family":"Straubinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jit150","article-title":"Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa","volume":"208","author":"Abbas","year":"2013","journal-title":"J. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/00498250110052779","article-title":"Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man","volume":"31","author":"Abel","year":"2001","journal-title":"Xenobiotica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1365-2125.2008.03137.x","article-title":"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects","volume":"65","author":"Abel","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2125.2008.03130.x","article-title":"Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers","volume":"65","author":"Abel","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antiviral Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women","volume":"367","author":"Baeten","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"New Engl. J. Med."},{"key":"B8","article-title":"High Uptake and Reduced HIV-1 Incidence in an Open-Label Trial of the Dapivirine Ring","volume-title":"25th Conference on Retroviruses and Opportunistic Infections (2018 CROI Foundation\/International Antiviral Society-USA)","author":"Baeten","year":"2018"},{"key":"B9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","article-title":"CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: roles in viral entry, tropism, and disease","volume":"17","author":"Berger","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/AAC.00968-06","article-title":"cathepsin a is the major hydrolase catalyzing the intracellularhydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131","volume":"51","author":"Birkus","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1254031","DOI":"10.1126\/science.1254031","article-title":"Selection bias at the heterosexual HIV-1 transmission bottleneck","volume":"345","author":"Carlson","year":"2014","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13318-018-0526-2","article-title":"Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor","volume":"44","author":"Cattaneo","year":"2018","journal-title":"Eur. J. Drug Metab.Pharmacokinet."},{"key":"B13","first-page":"17","article-title":". HIV Surveillance Report, 2017","volume":"29","year":"2018"},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2125.2008.03139.x","article-title":"A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects","volume":"65","author":"Chan","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir Disoproxil Fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10928-017-9554-9","article-title":"Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data","volume":"44","author":"Collins","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine","volume":"214","author":"Cottrell","year":"2016","journal-title":"J. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jac\/dkx064","article-title":"Single-dose pharmacokinetics of tenofovir alafenamide and itsactive metabolite in the mucosal tissues","volume":"72","author":"Cottrell","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1128\/AAC.42.3.687","article-title":"Pharmacokinetics and bioavailability of the anti-humanimmunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) indogs","volume":"42","author":"Cundy","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989\u20132009)","volume":"85","author":"de B\u00e9thune","year":"2010","journal-title":"Antiviral Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human-immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"Duwal","year":"2012","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/psp4.12095","article-title":"Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1","volume":"5","author":"Duwal","year":"2016","journal-title":"CPT: Pharmacometrics Syst. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1006740","DOI":"10.1371\/journal.pcbi.1006740","article-title":"Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis","volume":"15","author":"Duwal","year":"2019","journal-title":"PloS Comput. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e74404","DOI":"10.1371\/journal.pone.0074404","article-title":"Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel","volume":"8","author":"Gao","year":"2013","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0167696","DOI":"10.1371\/journal.pone.0167696","article-title":"Multicompartmental pharmacokinetic model of tenofovir delivery to the rectal mucosa by an enema","volume":"12","author":"Gao","year":"2017","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1098\/rstb.1993.0143","article-title":"Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes","volume":"342","author":"Garnett","year":"1993","journal-title":"Philos. Trans. R. Soc. London. Ser. B: Biol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1124\/jpet.118.251009","article-title":"A pharmacokinetic\/pharmacodynamic model to predict effective HIV prophylaxis dosing strategies for people who inject drugs","volume":"367","author":"Garrett","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36004-z","article-title":"Deducing mucosal pharmacokinetics and pharmacodynamics of the Anti-HIV molecule tenofovir from measurements in blood","volume":"9","author":"Govil","year":"2019","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"New Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"Haberer","year":"2015","journal-title":"AIDS"},{"key":"B37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ejps.2016.08.037","article-title":"Pharmacokinetic modeling of a gel-delivered dapivirine microbicide in humans","volume":"93","author":"Halwes","year":"2016","journal-title":"Eur. J. Pharm Sci."},{"key":"B38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: isthere a true difference in efficacy and safety","volume":"4","author":"Hill","year":"2018","journal-title":"J. Virus Erad."},{"key":"B39","first-page":"27","article-title":"Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue","volume":"2018","author":"Kay","year":"2018","journal-title":"Abstr. Annu. Meet. Popul. Ap. Group Europe"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/bcp.13625","article-title":"Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations","volume":"84","author":"Kay","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","author":"Kearney","year":"2004"},{"key":"B42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"homozygous defect in HIV-1 Coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"B44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"New Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"Lancet HIV"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1345\/aph.1D302","article-title":"Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor","volume":"38","author":"Modrzejewski","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"B47","first-page":"89","article-title":"Modelling HIV\/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission","volume":"80","author":"Nagelkerke","year":"2002","journal-title":"Bull. World Health Organ."},{"key":"B48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2334-7-16","article-title":"Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa","volume":"7","author":"Nagelkerke","year":"2007","journal-title":"BMC Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"New Engl. J. Med."},{"key":"B50","article-title":"HIV incidence and adherence in DREAM: an open-label trial of dapivirine vaginal ring","volume-title":"25th Conference on Retroviruses and Opportunistic Infections (2018 CROI Foundation\/International Antiviral Society-USA)","author":"Nel","year":"2018"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e59549","DOI":"10.1371\/journal.pone.0059549","article-title":"Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study","volume":"8","author":"Nichols","year":"2013","journal-title":"PloS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/1040841X.2013.867829","article-title":"Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; Overview of viral entry inhibition","volume":"41","author":"Panos","year":"2015","journal-title":"Crit. Rev. in Microbiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/QAD.0b013e328344037a","article-title":"Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings","volume":"25","author":"Phillips","year":"2011","journal-title":"Aids"},{"key":"B54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","article-title":"Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV","volume":"54","author":"Rajoli","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14787210.2014.863708","article-title":"Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor","volume":"12","author":"Ripamonti","year":"2014","journal-title":"Expert Rev. Anti-Infective Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral Activity, Safety, and Pharmacokinetics\/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1\u2013Positive Adults","volume":"63","author":"Ruane","year":"2013","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"B57","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1023\/A:1012108719462","article-title":"Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs","volume":"14","author":"Shaw","year":"1997","journal-title":"Pharm. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B59","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"B61","article-title":"Truvada NDA 21752\/S-030 Supplement Approval Letter. Application number: 021752Orig1s30","year":"2012"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1128\/AAC.02058-13","article-title":"Population pharmacokinetics of emtricitabine in HIV-1-infectedadult patients","volume":"58","author":"Valade","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1128\/AAC.01517-15","article-title":"Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study","volume":"59","author":"Valade","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure Prophylaxis for HIV Infection among African Women","volume":"367","author":"Van Damme","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1097\/01.aids.0000433237.63560.20","article-title":"Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models","volume":"27","author":"Van De Vijver","year":"2013","journal-title":"Aids"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e2077","DOI":"10.1371\/journal.pone.0002077","article-title":"The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study","volume":"3","author":"Vissers","year":"2008","journal-title":"PloS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e18204","DOI":"10.1371\/journal.pone.0018204","article-title":"HIV Quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs","volume":"6","author":"von Kleist","year":"2011","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1002359","DOI":"10.1371\/journal.pcbi.1002359","article-title":"HIV-1 polymerase inhibition by nucleoside analogs: cellular-and kinetic parameters of efficacy, susceptibility and resistance selection","volume":"8","author":"von Kleist","year":"2012","journal-title":"PloS Comput. Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T17:00:50Z","timestamp":1665680450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":68,"alternative-id":["10.3389\/fphar.2019.01514"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01514","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"article-number":"1514"}}